Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 25, 2022 10:10am
116 Views
Post# 34847765

RE:RE:RE:RE:RE:Exercise of Options

RE:RE:RE:RE:RE:Exercise of Options

Yes!  He "appreciates the company's willingness to take risks", but he appears unwilling to do this himself!  His actions don't sit well with that article.  

PWIB123 wrote: Remember this article from last year?  I'd say he has a deep understanding of what's happening inside the company.  https://www.vanguardlawmag.com/case-studies/jocelyn-lafond-theratechnologies/
 

PWIB123 wrote: Why aren't those filings showing on Sedar or Edgar?  Sometimes companies will put an explanation in the description of an insider trade, such as donated to charity or forfeiture of shares to pay taxes from shareholder compensation plan.

The timing of this insider sell couldn't be any worse.  I have been so excited about the near-term prospects, but this definitely tempers my hope...a lot.  Who would sell if they thought there was huge upside in the near term?  I don't care what your personal circumstances are, you find a way.  This doens't look good at all!

palinc2000 wrote: This is really crappy at least optically
I dont want to spend the time to search what was the expiration date of the options but even if the expiry date was close he could have exercised now and not sell That would have been an out of pocket cost of 7600 $ now plus additional income taxes in April 2022 of less than 10000$

I hope this is not another Lyne moment!!!

 




<< Previous
Bullboard Posts
Next >>